John H. Malfetano

6.4k total citations · 2 hit papers
81 papers, 4.8k citations indexed

About

John H. Malfetano is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, John H. Malfetano has authored 81 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Reproductive Medicine, 30 papers in Surgery and 28 papers in Obstetrics and Gynecology. Recurrent topics in John H. Malfetano's work include Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (24 papers) and Colorectal and Anal Carcinomas (12 papers). John H. Malfetano is often cited by papers focused on Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (24 papers) and Colorectal and Anal Carcinomas (12 papers). John H. Malfetano collaborates with scholars based in United States, United Kingdom and Netherlands. John H. Malfetano's co-authors include Brian N. Bundy, Wesley C. Fowler, Daniel L. Clarke‐Pearson, Charles W. Whitney, Shu‐Yuan Liao, Edward V. Hannigan, William T. Sause, Howard D. Homesley, John A. Blessing and Robert A. Ambros and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Journal of Obstetrics and Gynecology.

In The Last Decade

John H. Malfetano

80 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study

1999 1.2k citations Brian N. Bundy, John H. Malfetano et al. Journal of Clinical Oncology profile →
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

1997 532 citations Martin Gore, J Carmichael et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John H. Malfetano United States	34	2.7k	2.0k	1.9k	1.3k	1.1k	81	4.8k
Wesley C. Fowler United States	31	3.6k 1.3×	2.1k 1.1×	1.7k 0.9×	904 0.7×	1.5k 1.3×	112	5.5k
Frederick B. Stehman United States	36	3.8k 1.4×	2.4k 1.2×	2.3k 1.2×	1.1k 0.9×	2.0k 1.8×	111	6.0k
Stefano Greggi Italy	40	2.4k 0.9×	1.5k 0.8×	2.4k 1.3×	1.1k 0.9×	988 0.9×	142	4.6k
J. Taylor Wharton United States	48	2.9k 1.1×	2.5k 1.3×	2.7k 1.4×	2.0k 1.6×	1.5k 1.4×	166	7.5k
Hugh M. Shingleton United States	37	3.0k 1.1×	1.7k 0.9×	1.8k 0.9×	939 0.7×	1.7k 1.6×	141	4.8k
U. Beller Israel	20	2.7k 1.0×	1.1k 0.5×	2.6k 1.4×	824 0.7×	893 0.8×	57	4.6k
Jacob Rotmensch United States	33	2.4k 0.9×	1.1k 0.6×	1.6k 0.8×	796 0.6×	533 0.5×	132	4.5k
Harry J. Long United States	36	2.2k 0.8×	1.1k 0.5×	1.3k 0.7×	1.7k 1.3×	1.1k 1.0×	95	4.8k
Mitchell Morris United States	34	4.1k 1.5×	2.7k 1.3×	2.0k 1.1×	1.1k 0.9×	1.8k 1.7×	73	5.8k
J Bénda United States	26	2.3k 0.9×	1.1k 0.6×	1.5k 0.8×	740 0.6×	854 0.8×	72	3.7k

Countries citing papers authored by John H. Malfetano

Since Specialization

Citations

This map shows the geographic impact of John H. Malfetano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Malfetano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Malfetano more than expected).

Fields of papers citing papers by John H. Malfetano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Malfetano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Malfetano. The network helps show where John H. Malfetano may publish in the future.

Co-authorship network of co-authors of John H. Malfetano

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Malfetano. A scholar is included among the top collaborators of John H. Malfetano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Malfetano. John H. Malfetano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutton, Gregory P., Brian N. Bundy, Tapan Kumar Roy, et al.. (2005). Whole Abdominal Radiotherapy in the Adjuvant Treatment of Patients With Stage III and IV Endometrial Cancer: A Gynecology Oncology Group Study. Obstetrical & Gynecological Survey. 60(10). 648–649. 13 indexed citations

Gore, Martin, Amit M. Oza, Gordon Rustin, et al.. (2002). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European Journal of Cancer. 38(1). 57–63. 82 indexed citations

Carlson, J. Andrew, Andrzej Słomiński, K Weismann, et al.. (2002). Melanocytic Proliferations Associated With Lichen Sclerosus. Archives of Dermatology. 138(1). 77–87. 75 indexed citations

Fowler, Jeffrey M., John A. Blessing, Robert A. Burger, & John H. Malfetano. (2002). Phase II Evaluation of Oral Trimetrexate in Mixed Mesodermal Tumors of the Uterus: A Gynecologic Oncology Group Study. Gynecologic Oncology. 85(2). 311–314. 14 indexed citations

Carlson, J. Andrew, Shantu Amin, John H. Malfetano, et al.. (2001). Concordant p53 and mdm-2 Protein Expression in Vulvar Squamous Cell Carcinoma and Adjacent Lichen Sclerosus. Applied immunohistochemistry & molecular morphology. 9(2). 150–163. 18 indexed citations

Ross, Jeffrey S., et al.. (2001). Decreased CD44 Standard Form Expression Correlates With Prognostic Variables in Ovarian Carcinomas. American Journal of Clinical Pathology. 116(1). 122–128. 36 indexed citations

Asbury, Robert F., John A. Blessing, Richard E. Buller, et al.. (1998). Amonafide in Patients With Leiomyosarcoma of the Uterus. American Journal of Clinical Oncology. 21(2). 145–146. 15 indexed citations

Riben, Michael, John H. Malfetano, Tipu Nazeer, et al.. (1997). Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.. PubMed. 10(8). 823–31. 46 indexed citations

Broun, E. Randolph, et al.. (1997). A Phase II Trial of Edatrexate in Previously Treated Squamous Cell Cervical Cancer. American Journal of Clinical Oncology. 20(1). 78–80. 6 indexed citations

10.

Ambros, Robert A., et al.. (1996). Clinicopathologic Features of Vulvar Squamous Cell Carcinomas Exhibiting Prominent Fibromyxoid Stromal Response. International Journal of Gynecological Pathology. 15(2). 137–145. 36 indexed citations

11.

Nazeer, Tipu, et al.. (1995). Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. American Journal of Obstetrics and Gynecology. 173(6). 1829–1834. 18 indexed citations

12.

Malfetano, John H., et al.. (1993). Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer. 71(11). 3703–3706. 45 indexed citations

13.

Muss, Hyman B., et al.. (1992). Echinomycin (NSC 526417) in Recurrent and Metastatic Nonsquamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology. 15(4). 363–364. 6 indexed citations

14.

Kadar, Nicholas, Howard D. Homesley, & John H. Malfetano. (1992). Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecologic Oncology. 46(2). 145–149. 104 indexed citations

15.

Malfetano, John H.. (1990). Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecologic Oncology. 39(1). 82–84. 76 indexed citations

16.

Malfetano, John H., et al.. (1990). Incidental Cholecystectomy in the Treatment of Gynecologic Malignancy. Journal of Gynecologic Surgery. 6(3). 195–198. 2 indexed citations

17.

Heller, Paul B., John H. Malfetano, Brian N. Bundy, D Barnhill, & Takashi Okagaki. (1990). Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: Extended diagnostic evaluation for paraaortic node metastasis—A Gynecologic Oncology Group study. Gynecologic Oncology. 38(3). 425–430. 156 indexed citations

18.

Sutton, Gregory P., John A. Blessing, Howard D. Homesley, M L Berman, & John H. Malfetano. (1989). Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology. 7(11). 1672–1676. 94 indexed citations

19.

Piver, M. Steven, John H. Malfetano, Trudy R. Baker, Shashikant B. Lele, & David L. Marchetti. (1989). Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: A preliminary report. Gynecologic Oncology. 35(1). 69–72. 18 indexed citations

20.

Malfetano, John H.. (1986). Skin metastases from cervical cancer: A fatal event. Gynecologic Oncology. 24(2). 177–182. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact